i am on tirzepatide and not losing weight Why Tirzepatide? Your Questions Answered Why Am I Not Losing

Description

The FDA is unequivocal that "retatrutide and cagrilintide cannot be used in compounding under federal law." "These are not components of FDA-approved drugs and have not been found safe and effective for any condition," the agency said in drug safety information posted online

Healthcare professionals can help create an appropriate plan for transitioning or adjusting treatment if necessary

For years, compounding pharmacies have served as a vital, lawful, and intentional component for the U.S

According to NICE guidance (TA875 for semaglutide and TA664 for liraglutide), GLP-1 receptor agonists for weight management should only be prescribed when specific criteria are met

95% medication adherence in the first month 84% of prescribed patients engage with in-app content 56% use Med Tracker (where side effects can also be tracked) 56% engage in meal logging, with an average of 35 meals logged in the first month Patients log weight 1-2 times per week, on average, over the first 8 weeks of treatment Patients use Noom Move workouts an average of 6.9 times in the first month 45% engage with side-effect support in Nooms Success Kit Noom appreciates the potential of the new PDURS framework because it provides a way to put a software product on the drug label in an evidence-based way